
uniQure (QURE) Stock Forecast & Price Target
uniQure (QURE) Analyst Ratings
Bulls say
uniQure is a biotechnology company with a positive outlook as it focuses on developing gene therapies for genetic and other devastating diseases, such as hemophilia, Huntington's disease, and cardiovascular diseases. The company has a strong pipeline of products and services, including collaborations with Bristol Myers Squibb. Additionally, its financials show a stable cash runway and disciplined portfolio management. Clinical risks and reliance on the success of its lead development candidate, AMT-130, remain key factors to monitor.
Bears say
uniQure is a promising biotechnology company with a strong focus on developing effective gene therapies for various genetic diseases. However, the negative outlook stems from several key risks that could hinder the company's potential for success. These risks include potential delays in the U.S. regulatory approval for its lead product candidate AMT-130, which could impact its timeline and revenue projections. Additionally, the company heavily relies on this candidate for success, which poses significant financial risks in case of failure. Finally, uniQure faces competition and a volatile stock market, which could affect its overall commercial success.
This aggregate rating is based on analysts' research of uniQure and is not a guaranteed prediction by Public.com or investment advice.
uniQure (QURE) Analyst Forecast & Price Prediction
Start investing in uniQure (QURE)
Order type
Buy in
Order amount
Est. shares
0 shares